HARBOR研究中新生血管性年龄相关性黄斑变性的黄斑萎缩
HARBOR研究事后分析评估1095只眼接受雷珠单抗0.5mg或2.0mg每月或PRN治疗24个月后黄斑萎缩情况。基线黄斑萎缩检出率11.2%,24个月时无基线萎缩眼中29.4%新发黄斑萎缩。存在黄斑萎缩情况下仍有临床显著BCVA获益。
要点
- 基线黄斑萎缩检出率为11.2%(123/1095眼)。
- 24个月时无基线萎缩眼中29.4%(229/778眼)可检出黄斑萎缩。
- 雷珠单抗剂量与黄斑萎缩发生无关,每月vs PRN治疗与黄斑萎缩关联未达统计学显著(HR 1.29 [0.99-1.68])。
核心结论
- HARBOR研究中雷珠单抗治疗24个月后29%的研究眼可检出新生黄斑萎缩。
- 存在黄斑萎缩情况下24个月内仍获得临床显著BCVA获益。
- 基线无视网膜下液、有视网膜内囊样积液、对侧眼萎缩与24个月时黄斑萎缩存在相关。
- 基于现有数据,HARBOR研究中雷珠单抗对新生血管性AMD的获益在24个月内超过黄斑萎缩发生的风险,但未评估超过2年的结局。
研究设计与样本
- HARBOR研究(NCT00891735)的事后分析,该研究为3期多中心、前瞻性、随机、双盲、活性治疗对照临床试验。
- 纳入1095只可评估的研究眼,为继发于新生血管性AMD的中心凹下脉络膜新生血管(CNV),接受雷珠单抗0.5mg或2.0mg每月或PRN治疗。
- 对基线和第3、12、24个月的荧光素眼底血管造影(FA)和彩色眼底照相由设盲的阅片者回顾性评估黄斑萎缩。
主要发现
- 基线时黄斑萎缩检出率为11.2%(123/1095眼)。
- 第24个月时,无基线萎缩眼中29.4%(229/778眼)可检出黄斑萎缩。
- 有和无基线黄斑萎缩的眼在第24个月时较基线均有显著平均BCVA提升(字母数[95%CI]:分别为+6.7[4.1-9.3]和+9.1[8.0-10.2])。
- 第24个月时有和无黄斑萎缩的眼平均BCVA分别为62.0[60.3-63.7]和64.7[63.2-66.3]字母。
- 第24个月黄斑萎缩存在的基线危险因素包括视网膜内囊样积液(HR 2.45[1.76-3.42])和对侧眼萎缩(HR 2.02[1.42-2.87]),视网膜下液与较低黄斑萎缩风险相关(HR 0.50[0.33-0.74])。
关键数值与推荐
- 黄斑萎缩定义为:边界清晰的脱色素区伴脉络膜血管可见度增加,直径≥250μm,对应FA上边界清晰的平坦染色区,排除视网膜色素上皮撕裂相关的萎缩。
- 萎缩评估包括紧邻CNV病变内、邻近及非邻近CNV的萎缩。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出未评估超过2年的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate macular atrophy (MA) presence in the 24-month HARBOR study (NCT00891735) for neovascular age-related macular degeneration (AMD). DESIGN: Post hoc analysis of a phase 3 multicenter, prospective, randomized, double-masked, active treatment-controlled clinical trial. PARTICIPANTS: Evaluable subjects (N = 1095) with subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD treated with ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN). METHODS: Fluorescein angiograms (FAs) and color fundus photographs at baseline and months 3, 12, and 24 were retrospectively graded by masked graders for MA: well-defined areas of depigmentation with increased choroidal vessel visibility, diameter ≥250 μm, corresponding to flat areas of well-demarcated staining on FA, excluding atrophy associated with retinal pigment epithelium tears. Atrophy immediately within, adjacent, and nonadjacent to CNV lesions was included. MAIN OUTCOME MEASURES: Macular atrophy incidence, best-corrected visual acuity (BCVA). RESULTS: At baseline, MA was detected in 11.2% (123/1095) of study eyes. At month 24, 29.4% (229/778) of eyes without baseline atrophy had detectable MA. Eyes with and without baseline MA had significant mean BCVA gains from baseline at month 24 (letters [95% confidence interval]: +6.7 [4.1-9.3]; +9.1 [8.0-10.2], respectively). Among eyes with and without MA at month 24, mean month 24 BCVA was 62.0 [60.3-63.7] and 64.7 [63.2-66.3] letters, respectively. Baseline risk factors for month 24 MA presence included intraretinal cysts (hazard ratio [HR], 2.45 [1.76-3.42]) and fellow eye atrophy (HR, 2.02 [1.42-2.87]); subretinal fluid was associated with a lower MA risk (HR, 0.50 [0.33-0.74]). Ranibizumab dose was not associated with MA development. Monthly versus PRN treatment trended toward an association with MA (HR, 1.29 [0.99-1.68]), but was not statistically significant. CONCLUSIONS: New MA was detected in 29% of study eyes after 24 months of treatment. Clinically significant BCVA gains were achieved with MA present over 24 months. Baseline subretinal fluid absence, intraretinal cyst presence, and fellow eye atrophy presence were associated with month 24 MA presence. With existing data, the benefits of ranibizumab for neovascular AMD outweighed the risk of MA development over 24 months in HARBOR, although outcomes >2 years were not evaluated.
引用
- Sadda SR, Tuomi LL, Ding B, et al. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018. PMID: 29477692. doi:10.1016/j.ophtha.2017.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。